Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte...
31 KB (2,727 words) - 21:26, 26 January 2024
'off-label'. In November 2010, an FDA advisory panel recommended approving belimumab (Benlysta) as a treatment for the pain and flare-ups common in lupus....
129 KB (14,190 words) - 06:36, 19 October 2024
and CEO. Benlysta (belimumab) received U.S. Food and Regulatory Administration approval for use in lupus in March 2011. Belimumab was being developed...
11 KB (1,095 words) - 21:02, 24 August 2024
mycophenolate, cyclophosphamide, low dose IL-2, intravenous immunoglobulins, and belimumab. Omalizumab is a monoclonal antibody that interacts with the binding site...
21 KB (1,860 words) - 04:32, 30 October 2024
first new drug for lupus in more than 50 years to be used in the US, belimumab. In addition to medical therapy, cognitive behavioral therapy has also...
18 KB (1,987 words) - 02:33, 17 September 2024
US$3 billion; the companies had collaborated on developing the lupus drug Belimumab (Benlysta), albiglutide for type 2 diabetes, and darapladib for atherosclerosis...
135 KB (12,155 words) - 22:52, 16 October 2024
Bactroban (mupirocin) Becotide (beclomethasone dipropionate) Benlysta (belimumab) Betnovate (betamethasone valerate) Blenrep (belantamab mafodotin) Breo...
7 KB (628 words) - 18:58, 27 December 2023
and azathioprine. Newer targeted medications, including omalizumab and belimumab, have also been used. Urticarial vasculitis is featured prominently in...
6 KB (715 words) - 07:24, 4 August 2023
Adalimumab (Humira) for rheumatoid arthritis and other inflammatory conditions Belimumab (Benlysta) for lupus Cladribine (Leustatin) for hairy cell leukemia Purification...
24 KB (2,416 words) - 02:55, 26 October 2024
(TL1A, TNFSF15) Recombinant proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab...
49 KB (6,232 words) - 07:00, 22 October 2024
Galiximab CD147/Basigin Gavilimomab CD154 Frexalimab Ruplizumab BLyS Belimumab CAT Bertilimumab Lerdelimumab Metelimumab Integrin Natalizumab Vedolizumab...
7 KB (299 words) - 13:45, 27 April 2024
marketed by Abbvie, formerly Abbott Laboratories. CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved...
91 KB (8,496 words) - 16:05, 19 August 2024
predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding...
6 KB (483 words) - 08:50, 31 December 2023
(TL1A, TNFSF15) Recombinant proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab...
5 KB (305 words) - 05:22, 23 October 2024
antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma Belimumab Benlysta mab human B-cell activating factor (BAFF) Y systemic lupus erythematosus...
137 KB (4,083 words) - 21:25, 19 October 2024
and neuropathy, biologic immunosuppressant drugs such as rituximab and belimumab that work via B-cell pathology are often used and have less toxic profiles...
87 KB (9,205 words) - 22:55, 18 October 2024
(TL1A, TNFSF15) Recombinant proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab...
8 KB (316 words) - 13:53, 10 September 2024
(INN) belarizine (INN) belatacept (USAN, INN) Beldin belfosdil (INN) belimumab (USAN) belinostat (USAN, INN) Belix Bellafoline Bellatal Bellergal-S beloranib...
14 KB (621 words) - 19:38, 4 August 2024
L04AG01 Muromonab-CD3 L04AG02 Efalizumab L04AG03 Natalizumab L04AG04 Belimumab L04AG05 Vedolizumab L04AG06 Alemtuzumab L04AG07 Begelomab L04AG08 Ocrelizumab...
3 KB (367 words) - 15:37, 25 January 2024
(TL1A, TNFSF15) Recombinant proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab...
8 KB (501 words) - 13:55, 10 September 2024
Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab...
38 KB (4,316 words) - 10:24, 26 August 2024
protocol. She has explored other therapeutics, including voclosporin and belimumab. Alongside development new treatment strategies, Lightstone searched for...
8 KB (760 words) - 20:45, 7 July 2024
(TL1A, TNFSF15) Recombinant proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab...
24 KB (2,809 words) - 11:12, 20 August 2024
fusion-positive thyroid cancer, in radioactive iodine-refractory patients Belimumab GlaxoSmithKline active lupus nephritis Osimertinib AstraZeneca adjuvant...
34 KB (180 words) - 17:05, 14 October 2024
correlates with enhanced humoral immunity against malaria infection. Belimumab (Benlysta) is a monoclonal antibody developed by Human Genome Sciences...
25 KB (3,095 words) - 14:05, 12 March 2024
Prophylaxis of acute organ rejection in renal transplant 103764 Link belimumab Benlysta Human Genome Sciences 3/9/2011 intravenous fully human BLyS Systemic...
59 KB (4,170 words) - 07:03, 20 October 2024
Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab...
2 KB (87 words) - 01:28, 30 May 2023
adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab, belimumab, and ustekinumab. Extracts from some medicinal mushrooms are natural biological...
20 KB (1,640 words) - 02:38, 30 March 2024
the reproduction of B cells. This led to the development of a new drug, Belimumab, approved by the FDA in 2011 for systemic lupus erythematosus. Tschopp's...
13 KB (1,390 words) - 00:02, 23 March 2023
pathophysiology of autoimmune diseases provided foundations for the development of belimumab (TM Benlysta, an anti-BAFF monoclonal antibody), a milestone therapy approved...
24 KB (2,421 words) - 01:59, 11 May 2024